A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention.
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2017
At a glance
- Drugs AMG-301 (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Amgen
- 14 Sep 2017 Status changed from not yet recruiting to recruiting.
- 01 Aug 2017 Status changed from recruiting to not yet recruiting.
- 20 Jul 2017 New trial record